MRK is overvalued and will drop

[hajimow]

I shorted MRK by selling weekly Call 61 and 61.5. I rarely directly short the stock. But MRK going up 5% just by an approval of an application for a drug was a call for shorting.

 

[hajimow]

MRK imploding !!!

 

[Jamie J.]

MRK looks awful. Get rid of it as soon as possible

 

[Vincent S. Ashmore]

$ONCS interesting the big $MRK approval today was to use keytruda with chemo. They are looki g to expand the use of product...partnership?

 

[Jamie J.]

$ONCS interesting the big $MRK approval today was to use keytruda with chemo. They are looki g to expand the use of product...partnership?

Do you think it will save the situation? I doubt it.

 

[Vincent S. Ashmore]

Merck Is Best Performing DJIA Stock So Far in 2017

 

[hajimow]

Covered my short position today with a nice profit and increased my short position on MMM.

 

[hajimow]

MRK is again in short territory. Shorted on Thursday. Will drop to $60 in less than a week.

 

[ironchef]

No offense, but I still remember you told all of us to short MCD and that it won't be around in 5 years while all that time you kept selling puts on MCD, a bullish bet. Just a reminder, MCD is @ $124 today (~$85 then).

As for MRK, I won't short it because of one word: Keytruda.

Cheers.

 

[dealmaker]

FDA OKs Merck's Keytruda to treat cancers with genetic defects
Food and Drug Administration on Tuesday approved Merck & Co.'s Keytruda drug to treat tumors with a certain genetic defect -- the first time the agency has cleared a cancer drug for a use not tied to the site of a tumor. The FDA approved Keytruda to treat tumors with genetic defects known as "microsatellite instability" or "mismatch repair" deficiencies, which are present in an estimated 4 percent of cancers. (Morningstar)